Peginterferon Alfa-2A
| Evidence Level: L1 | Predicted Indications: 9 |
Table of Contents
Peginterferon Alfa-2A: Hepatitis E virus infection
One-Sentence Summary
Peginterferon alfa-2a is an antiviral, immune-modulating drug originally used for chronic hepatitis C and chronic hepatitis B infection.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hepatitis E virus infection |
| TxGNN Prediction Score | 0.9983 |
| Evidence Level | L1 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, peginterferon alfa-2a is a pegylated interferon with antiviral and immunomodulatory activity. It induces interferon-stimulated genes and enhances HBV-specific T cell and NK cell responses.
Its efficacy in chronic hepatitis C is established, and chronic hepatitis B is also listed among its original indications. Both are chronic hepatotropic viral infections in which host immune control matters, so the mechanism applies to hepatitis B. The high TxGNN score agrees with the large body of clinical evidence. Cytokine-profiling studies (for example PMID 32548156) further support the mechanism by identifying biomarkers that predict response.
Clinical Trial Evidence
Most of the trials below are in hepatitis B. The list is limited to 10 of the more relevant ones.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02604823 | Phase 4 | Completed | 307 | Efficacy and safety of 48 weeks of peginterferon alfa-2a in HBeAg-positive chronic hepatitis B, including naive and pretreated patients |
| NCT02097004 | Phase 4 | Completed | 111 | Therapeutic vaccination plus peginterferon for HBsAg seroclearance in patients with entecavir-induced response |
| NCT00614471 | Phase 4 | Completed | 219 | Peginterferon plus entecavir combination or sequence in HBeAg-positive patients |
| NCT02474316 | Phase 4 | Unknown | 366 | Switching HBeAg-positive patients from nucleoside analogue to peginterferon plus nucleoside analogue for 48 weeks vs entecavir |
| NCT03084250 | Phase 4 | Unknown | 150 | Nucleotide analogue with or without peginterferon in cirrhotic patients at high risk of HCC |
| NCT00661076 | Phase 3 | Completed | 10 | Peginterferon plus adefovir vs peginterferon alone in HBeAg-negative patients; very small sample |
| NCT02570191 | Phase 4 | Completed | 60 | Open-label study of efficacy and safety in HBeAg-negative chronic hepatitis B |
| NCT00436163 | Phase 4 | Completed | 39 | Post-marketing programme in treatment-naive Baltic patients with HBeAg-positive disease |
| NCT01237496 | Phase 3 | Completed | 17 | HBV-specific T cell response sub-study in HBeAg-negative patients; mechanistic and small |
| NCT01906580 | Phase 4 | Unknown | 105 | Combination or sequential peginterferon and entecavir in HBeAg-positive patients |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15987917 | 2005 | RCT | N Engl J Med | Peginterferon alfa-2a with or without lamivudine compared with lamivudine alone in HBeAg-positive chronic hepatitis B |
| 30549279 | 2019 | RCT | Hepatology | Entecavir plus peginterferon alfa-2a in adults with HBeAg-positive immune-tolerant infection |
| 26299874 | 2016 | Meta-analysis | Clin Res Hepatol Gastroenterol | Extended vs standard duration of peginterferon alfa-2a monotherapy in chronic hepatitis B |
| 30865588 | 2019 | Meta-analysis | Antivir Ther | Individual-participant-data analysis to identify the best peginterferon stopping rules |
| 22045673 | 2011 | Randomized trial | Hepatology | Shorter durations and lower doses linked to lower HBeAg seroconversion in genotypes B or C |
| 33720089 | 2021 | Randomized trial | J Pediatr Gastroenterol Nutr | Peginterferon plus lamivudine or entecavir in children with immune-tolerant chronic hepatitis B |
| 26700861 | 2015 | Randomized trial | Virol J | Long-term effects of peginterferon alfa-2a in Japanese patients with chronic hepatitis B |
| 19084016 | 2009 | Clinical trial | Gastroenterology | Peginterferon alfa-2a plus ribavirin in patients with dual HBV and HCV infection |
| 32548156 | 2020 | Cohort/biomarker | World J Clin Cases | Cytokines predict virological response to peginterferon alfa-2a |
| 26188762 | 2016 | Review | J Formos Med Assoc | Perspectives on dual hepatitis B and C infection in Taiwan |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02248077 | PEGASYS | Not specified | Not specified |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. The sample reviewed includes several Major interactions: bupropion, deferiprone, iopamidol, iohexol, samarium (153Sm) lexidronam and eltrombopag. Moderate interactions include metronidazole, tinidazole, naltrexone, rosuvastatin, simvastatin, warfarin, dicoumarol, chloroquine, pegvaliase, palifermin, strontium chloride Sr-89, and bowel-preparation products (picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes).
- Preclinical work (PMID 17049181) and the broader literature note that interferon-alpha can cause neuropsychiatric effects such as depression, and it is also associated with cardiotoxicity. Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Many Phase 3 and Phase 4 trials plus randomized trials and meta-analyses support peginterferon alfa-2a in chronic hepatitis B, and the drug is marketed in Canada. Because hepatitis B is already an established indication, this is a confirmation rather than new repurposing. Many of the larger trials are Phase 4 or open-label, and the Phase 3 trials are small.
To proceed, the following is needed:
- Canadian package insert warnings and contraindications (the safety review cannot be completed without them)
- Detailed mechanism of action data
- Approved indication text and dosage form for the Canadian license
- A review of the major drug interactions and a monitoring plan for neuropsychiatric and cardiac effects
Other predictions in this analysis: Hepatitis E virus infection has only indirect evidence (all listed trials are in HBV) and should be treated as a research question. Hepatitis A, animal viral hepatitis, Omsk hemorrhagic fever, Kyasanur forest disease and the cardiac predictions (heart conduction disease, heart neoplasm, heart valve disease, ventricular septal anomaly) are supported only by model scores or by non-efficacy data, and are recommended to be held.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.